Harvard Bioscience slumps after weak revenue forecast

Shares of Harvard Bioscience HBIO.O down 21.3% at 60 cents premarket

Co expects Q1 revenue between $19 million and $21 million, below analysts' estimate of $22.95 million - data compiled by LSEG

The company is also exploring alternative capital sources for refinancing outstanding indebtedness by June 30

HBIO says company faces substantial doubt about its ability to continue as going concern but expects available cash to finance operations while it works on credit agreement refinancing

As of last close, HBIO down ~64% YTD